Damora Therapeutics, Inc. SEC filings DMRA

Damora Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 20, 2026 (material agreement, change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.

Damora Therapeutics, Inc. SEC filings
Form Description Filed Period
DEF 14A Proxy statement Apr 29, 2026 Apr 29, 2026
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Dec 31, 2025 Feb 9, 2026
PRE 14A Preliminary proxy statement Dec 16, 2025 Dec 16, 2025
DEFA14A Additional proxy material Apr 30, 2025 —
DEF 14A Proxy statement Apr 30, 2025 Jun 18, 2025
PRE 14A Preliminary proxy statement Apr 17, 2025 Jun 18, 2025
DEF 14A Proxy statement Apr 29, 2024 Jun 20, 2024
PRE 14A Preliminary proxy statement Apr 16, 2024 Jun 20, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 14, 2023
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Apr 28, 2022
DEFA14A Additional proxy material Apr 14, 2021 —
DEF 14A Proxy statement Apr 14, 2021 May 26, 2021

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DMRA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1800315
Former names
Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.